A Aguado1, C Rodríguez2, S Martínez-Revelles1, M S Avendaño1, O Zhenyukh1, M Orriols2, J Martínez-González2, M J Alonso3, A M Briones1, D A Dixon4, M Salaices1. 1. Departamento de Farmacología, Universidad Autónoma de Madrid, Instituto de Investigación Hospital La Paz (IdiPAZ), Madrid, Spain. 2. Centro de Investigación Cardiovascular (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain. 3. Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain. 4. Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract
BACKGROUND AND PURPOSE: Angiotensin II (AngII) and IL-1β are involved in cardiovascular diseases through the induction of inflammatory pathways. HuR is an adenylate- and uridylate-rich element (ARE)-binding protein involved in the mRNA stabilization of many genes. This study investigated the contribution of HuR to the increased expression of COX-2 induced by AngII and IL-1β and its consequences on VSMC migration and remodelling. EXPERIMENTAL APPROACH: Rat and human VSMCs were stimulated with AngII (0.1 μM) and/or IL-1β (10 ng · mL(-1)). Mice were infused with AngII or subjected to carotid artery ligation. mRNA and protein levels were assayed by quantitative PCR, Western blot, immunohistochemistry and immunofluorescence. Cell migration was measured by wound healing and transwell assays. KEY RESULTS: In VSMCs, AngII potentiated COX-2 and tenascin-C expressions and cell migration induced by IL-1β. This effect of AngII on IL-1β-induced COX-2 expression was accompanied by increased COX-2 3' untranslated region reporter activity and mRNA stability, mediated through cytoplasmic HuR translocation and COX-2 mRNA binding. These effects were blocked by ERK1/2 and HuR inhibitors. VSMC migration was reduced by blockade of ERK1/2, HuR, COX-2, TXAS, TP and EP receptors. HuR, COX-2, mPGES-1 and TXAS expressions were increased in AngII-infused mouse aortas and in carotid-ligated arteries. AngII-induced tenascin-C expression and vascular remodelling were abolished by celecoxib and by mPGES-1 deletion. CONCLUSIONS AND IMPLICATIONS: The synergistic induction of COX-2 by AngII and IL-1β in VSMCs involves HuR through an ERK1/2-dependent mechanism. The HuR/COX-2 axis participates in cell migration and vascular damage. HuR might be a novel target to modulate vascular remodelling.
BACKGROUND AND PURPOSE:Angiotensin II (AngII) and IL-1β are involved in cardiovascular diseases through the induction of inflammatory pathways. HuR is an adenylate- and uridylate-rich element (ARE)-binding protein involved in the mRNA stabilization of many genes. This study investigated the contribution of HuR to the increased expression of COX-2 induced by AngII and IL-1β and its consequences on VSMC migration and remodelling. EXPERIMENTAL APPROACH: Rat and human VSMCs were stimulated with AngII (0.1 μM) and/or IL-1β (10 ng · mL(-1)). Mice were infused with AngII or subjected to carotid artery ligation. mRNA and protein levels were assayed by quantitative PCR, Western blot, immunohistochemistry and immunofluorescence. Cell migration was measured by wound healing and transwell assays. KEY RESULTS: In VSMCs, AngII potentiated COX-2 and tenascin-C expressions and cell migration induced by IL-1β. This effect of AngII on IL-1β-induced COX-2 expression was accompanied by increased COX-2 3' untranslated region reporter activity and mRNA stability, mediated through cytoplasmic HuR translocation and COX-2 mRNA binding. These effects were blocked by ERK1/2 and HuR inhibitors. VSMC migration was reduced by blockade of ERK1/2, HuR, COX-2, TXAS, TP and EP receptors. HuR, COX-2, mPGES-1 and TXAS expressions were increased in AngII-infused mouse aortas and in carotid-ligated arteries. AngII-induced tenascin-C expression and vascular remodelling were abolished by celecoxib and by mPGES-1 deletion. CONCLUSIONS AND IMPLICATIONS: The synergistic induction of COX-2 by AngII and IL-1β in VSMCs involves HuR through an ERK1/2-dependent mechanism. The HuR/COX-2 axis participates in cell migration and vascular damage. HuR might be a novel target to modulate vascular remodelling.
Authors: Mar Orriols; Anna Guadall; María Galán; Ingrid Martí-Pàmies; Saray Varona; Ricardo Rodríguez-Calvo; Ana María Briones; María A Navarro; Alicia de Diego; Jesús Osada; José Martínez-González; Cristina Rodríguez Journal: Thromb Haemost Date: 2014-07-03 Impact factor: 5.249
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Anke Doller; El-Sayed Akool; Andrea Huwiler; Roswitha Müller; Heinfried H Radeke; Josef Pfeilschifter; Wolfgang Eberhardt Journal: Mol Cell Biol Date: 2008-02-19 Impact factor: 4.272
Authors: Jian Zhang; Fangfang Zou; Juan Tang; Qianqian Zhang; Yanjun Gong; Qingsong Wang; Yujun Shen; Lixia Xiong; Richard M Breyer; Michael Lazarus; Colin D Funk; Ying Yu Journal: Circ Res Date: 2013-04-17 Impact factor: 17.367
Authors: Rahul B Dange; Deepmala Agarwal; Gustavo S Masson; Jorge Vila; Brad Wilson; Anand Nair; Joseph Francis Journal: Cardiovasc Res Date: 2014-03-25 Impact factor: 10.787
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: M S Avendaño; S Martínez-Revelles; A Aguado; M R Simões; M González-Amor; R Palacios; P Guillem-Llobat; D V Vassallo; L Vila; J García-Puig; L M Beltrán; M J Alonso; M V Cachofeiro; M Salaices; A M Briones Journal: Br J Pharmacol Date: 2016-03-21 Impact factor: 8.739
Authors: Andrea Aguado; Thierry Fischer; Cristina Rodríguez; Adrian Manea; José Martínez-González; Rhian M Touyz; Raquel Hernanz; M Jesús Alonso; Dan A Dixon; Ana M Briones; Mercedes Salaices Journal: J Hypertens Date: 2016-02 Impact factor: 4.844
Authors: Juliano Vilela Alves; Rafael Menezes da Costa; Camila André Pereira; Aline Garcia Fedoce; Carlos Alberto Aguiar Silva; Fernando Silva Carneiro; Núbia Souza Lobato; Rita C Tostes Journal: Front Immunol Date: 2020-07-31 Impact factor: 7.561